Found: 14
Select item for more details and to access through your institution.
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire.
- Published in:
- Rheumatology Advances in Practice, 2024, v. 8, n. 1, p. 1, doi. 10.1093/rap/rkae001
- By:
- Publication type:
- Article
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.
- Published in:
- Rheumatology Advances in Practice, 2020, v. 4, n. 2, p. 1, doi. 10.1093/rap/rkaa017
- By:
- Publication type:
- Article
Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.
- Published in:
- Frontiers in Immunology, 2022, v. 12, p. 1, doi. 10.3389/fimmu.2022.957201
- By:
- Publication type:
- Article
Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?
- Published in:
- Rheumatology, 2024, v. 63, p. SI86, doi. 10.1093/rheumatology/kead537
- By:
- Publication type:
- Article
Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience.
- Published in:
- Rheumatology, 2023, v. 62, n. 2, p. e18, doi. 10.1093/rheumatology/keac456
- By:
- Publication type:
- Article
338. An unusual cause of seizure.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
340. Reversible cerebral vasoconstriction syndrome in a patient with wegener and takayasu arteritis.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
339. Long-term biological treatment in 30 patients with large vessels vasculitis: 8 years' experience of a single italian center.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Retinal microvascular alterations in patients with active rheumatoid arthritis without cardiovascular risk factors: the potential effects of T cell co-stimulation blockade.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2024.1247024
- By:
- Publication type:
- Article
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting.
- Published in:
- Arthritis & Rheumatology, 2020, v. 72, n. 8, p. 1314, doi. 10.1002/art.41253
- By:
- Publication type:
- Article
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00433
- By:
- Publication type:
- Article
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. 1, doi. 10.3389/fphar.2021.666971
- By:
- Publication type:
- Article
Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1379611
- By:
- Publication type:
- Article
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS).
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 4, p. 691, doi. 10.3390/jpm13040691
- By:
- Publication type:
- Article